Vaccination with formulation of nanoparticles loaded with Leishmania amazonensis antigens confers protection against experimental visceral leishmaniasis in hamster.

dc.contributor.authorCabrera González, Marco Antonio
dc.contributor.authorGonçalves, Ana Alice Maia
dc.contributor.authorOttino, Jennifer
dc.contributor.authorLeite, Jaqueline Costa
dc.contributor.authorResende, Lucilene Aparecida
dc.contributor.authorMelo Júnior, Otoni Alves de Oliveira
dc.contributor.authorSilveira, Patricia
dc.contributor.authorCardoso, Mariana Santos
dc.contributor.authorFujiwara, Ricardo Toshio
dc.contributor.authorBueno, Lilian Lacerda
dc.contributor.authorSantos, Renato Lima
dc.contributor.authorCarvalho, Tatiane Furtado de
dc.contributor.authorGarcia, Giani Martins
dc.contributor.authorPaes, Paulo Ricardo de Oliveira
dc.contributor.authorGaldino, Alexsandro Sobreira
dc.contributor.authorChávez Fumagalli, Miguel Angel
dc.contributor.authorMelo, Marilia Martins
dc.contributor.authorLemos, Denise da Silveira
dc.contributor.authorMartins Filho, Olindo Assis
dc.contributor.authorDutra, Walderez Ornelas
dc.contributor.authorMosqueira, Vanessa Carla Furtado
dc.contributor.authorGiunchetti, Rodolfo Cordeiro
dc.date.accessioned2023-10-19T19:09:46Z
dc.date.available2023-10-19T19:09:46Z
dc.date.issued2023pt_BR
dc.description.abstractVisceral leishmaniasis (VL) is a fatal disease caused by the protozoa Leishmania infantum for which dogs are the main reservoirs. A vaccine against canine visceral leishmaniasis (CVL) could be an important tool in the control of human and CVL by reducing the infection pressure of L. infantum. Despite the CVL vaccine available on the market, the Brazilian Ministry of Health did not implement the use of it in their control programs. In this sense, there is an urgent need to develop more efficient vaccines. In this study, the association between two polymeric nanoformulations, (poly (D, L-lactic) acid (PLA) polymer) loading Leishmania amazonensis antigens, was evaluated as a potential immunobiological agent against VL using golden hamsters as an experimental model. The results indicated that no significant adverse reactions were observed in animals vaccinated with LAPSmP. LAPSmP presented similar levels of total anti-Leishmania IgG as compared to LAPSmG. The LAPSmP and LAPSmG groups showed an intense reduction in liver and spleen parasitic load by qPCR. The LAPSmP and LAPSmG vaccines showed exceptional results, indicating that they may be promising candidates as a VL vaccine.pt_BR
dc.identifier.citationCABRERA GONZÁLEZ, M. A. et al. Vaccination with formulation of nanoparticles loaded with Leishmania amazonensis antigens confers protection against experimental visceral leishmaniasis in hamster. Vaccines, v. 11, n. 1, artigo 111, 2023. Disponível em: <https://www.mdpi.com/2076-393X/11/1/111>. Acesso em: 01 ago. 2023.pt_BR
dc.identifier.doihttps://doi.org/10.3390/vaccines11010111pt_BR
dc.identifier.issn2076-393X
dc.identifier.urihttp://www.repositorio.ufop.br/jspui/handle/123456789/17623
dc.language.isoen_USpt_BR
dc.rightsabertopt_BR
dc.rights.licenseThis article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). Fonte: PDF do artigo.pt_BR
dc.subjectNanotechnologypt_BR
dc.subjectVaccinept_BR
dc.titleVaccination with formulation of nanoparticles loaded with Leishmania amazonensis antigens confers protection against experimental visceral leishmaniasis in hamster.pt_BR
dc.typeArtigo publicado em periodicopt_BR

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura Disponível
Nome:
ARTIGO_VaccinationFormulationNanoparticles.pdf
Tamanho:
3.47 MB
Formato:
Adobe Portable Document Format
Descrição:

Licença do pacote

Agora exibindo 1 - 1 de 1
Nenhuma Miniatura Disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição: